You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recommended Dose

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial (BP-C2)

Not yet recruiting
  • Prostate Cancer
  • (no location specified)
Jan 10, 2023

Prostate Cancer, Prostate Adenocarcinoma, Prostate Tumor Trial (Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log)

Not yet recruiting
  • Prostate Cancer
  • +3 more
  • Abiraterone Oral Tablet
  • +3 more
  • (no location specified)
Apr 1, 2022

Covid19 Trial in Hakata (DS-5670a, Placebo)

Completed
  • Covid19
  • DS-5670a
  • Placebo
  • Hakata, Fukuoka, Japan
    SOUSEIKAI Hakata Clinic
Aug 29, 2022

Multiple Myeloma Trial in Boston (BMS-986393, Alnuctamab, Mezigdomide)

Not yet recruiting
  • Multiple Myeloma
  • Boston, Massachusetts
  • +1 more
Nov 2, 2023

Ovarian Cancer Trial in Lexington (Artemisia annua 450mg, Artemisia annua 900mg, Artemisia annua 1350mg)

Recruiting
  • Ovarian Cancer
  • Artemisia annua 450mg
  • +4 more
  • Lexington, Kentucky
    University of Kentucky
Jan 4, 2023

Brain Tumor Trial in Houston (tepotinib, tepotinib plus osimertinib)

Not yet recruiting
  • Brain Tumor
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

Not yet recruiting
  • IDH1-mutant Cholangiocarcinoma
  • (no location specified)
Jun 29, 2023

Advanced Solid Tumors With MAPK Pathway Mutations Trial in Nedlands (D3S-002)

Not yet recruiting
  • Advanced Solid Tumors With MAPK Pathway Mutations
  • Nedlands, Western Australia, Australia
    D3 Bio Investigative Site
May 24, 2023

Solid Tumor, Adult Trial in Belgium, France (DT-9081 - dose escalation, DT-9081 - expansion)

Recruiting
  • Solid Tumor, Adult
  • DT-9081 - dose escalation
  • DT-9081 - expansion
  • Anderlecht, Belgium
  • +3 more
Jan 5, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Active, not recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
  • Yamagata, Japan
    Yamagata University Hospital
Feb 21, 2022

Cancer, Prostate Cancer, Metastatic Cancer Trial (177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended

Not yet recruiting
  • Cancer
  • +3 more
  • 177Lu-PSMA-I&T - escalating renal absorbed dose
  • 177Lu-PSMA-I&T - recommended phase 2 regime
  • (no location specified)
Jun 14, 2023

Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma Trial (Lurbinectedin)

Not yet recruiting
  • Refractory Ewing Sarcoma
  • +2 more
  • (no location specified)
Feb 15, 2023

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Denmark, Norway, Sweden (KAND567, Carboplatin)

Recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Odense, Denmark
  • +3 more
Oct 16, 2023

Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I Trial in Los Angeles (Pharmacokinetic Study,

Not yet recruiting
  • Recurrent Bladder Carcinoma
  • +2 more
  • Pharmacokinetic Study
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Jan 31, 2023

Advanced Malignant Solid Tumors Trial in Shanghai (HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion

Recruiting
  • Advanced Malignant Solid Tumors
  • HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 30, 2021

Aortic Valve Stenosis, Multidetector Computed Tomography, Vitamin K 2 Trial in Odense (Menaquinone-7 720 µg/day including the

Completed
  • Aortic Valve Stenosis
  • +3 more
  • Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).
  • Placebo
  • Odense, Odense C, Denmark
    Department of Cardiology, Odense University Hospital
Sep 28, 2022

Advanced Solid Tumor Trial (HLX23)

Withdrawn
  • Advanced Solid Tumor
  • Los Angeles, California
  • +5 more
Jan 13, 2023

Advanced Cancer, Metastatic Cancer Trial (Q901)

Recruiting
  • Advanced Cancer
  • Metastatic Cancer
  • Phoenix, Arizona
  • +5 more
Sep 1, 2022

Advanced Renal Cell Carcinoma Trial in Spain (Pazopanib + interferon alpha 2A)

Completed
  • Advanced Renal Cell Carcinoma
  • Pazopanib + interferon alpha 2A
  • Hospitalet de Llobregat, Barcelona, Spain
  • +12 more
Mar 9, 2022

Glioblastoma Trial in Milwaukee (Gallium maltolate (500 mg), Gallium maltolate (1,000 mg), Gallium maltolate (1,500 mg))

Recruiting
  • Glioblastoma
  • Gallium maltolate (500 mg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Sep 20, 2022

Hepatocellular Carcinoma, Liver Cancer, Liver Tumor Trial in United States (ET140203 autologous T cell product)

Recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • ET140203 autologous T cell product
  • Duarte, California
  • +3 more
Jul 1, 2022

Geographic Atrophy, Age-Related Macular Degeneration Trial in Barcelona (postbiotics (IGENH35.3A), vitamins (AREDS formulation

Active, not recruiting
  • Geographic Atrophy
  • Age-Related Macular Degeneration
  • postbiotics (IGENH35.3A)
  • vitamins (AREDS formulation and recommended daily dose)
  • Barcelona, Spain
    Institut de la Màcula
Jun 18, 2022

Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer Trial in Aurora, Nashville, Houston

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +4 more
  • Aurora, Colorado
  • +2 more
Apr 18, 2022

Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma Trial in Leicester (RSO-021)

Recruiting
  • Malignant Pleural Effusion
  • +3 more
  • Leicester, United Kingdom
  • +5 more
Oct 28, 2022

AL Amyloidosis, Amyloidosis Trial in Stanford, Boston, Rochester (Belantamab mafodotin 2.5 mg/kg (6 weeks), Belantamab mafodotin

Not yet recruiting
  • AL Amyloidosis
  • Amyloidosis
  • Belantamab mafodotin 2.5 mg/kg (6 weeks)
  • +4 more
  • Stanford, California
  • +3 more
Jul 25, 2022